Can I Take Vitamin B6 with Lisinopril?

Lisinopril is a generic angiotensin-converting enzyme (ACE) inhibitor sold under brand names including Prinivil and Zestril, FDA-approved for hypertension, heart failure, and post-myocardial-infarction management. Vitamin B6 refers to a group of related compounds, pyridoxine, pyridoxal, and pyridoxamine, sold over the counter as a standalone supplement or as part of multivitamin and B-complex products; it is a nutrient, not a regulated drug, and the FDA does not evaluate supplement doses for safety before marketing.

The direct answer, with its boundary

Vitamin B6 and lisinopril act on different systems and are cleared through different pathways, so no interaction mechanism connects them, and no major interaction database entry for this pair is described in the source material reviewed for this page. That absence of a described interaction is not the same as a formal safety study confirming co-administration; it reflects that the two agents have no plausible shared target. The dose that matters is B6's own dose, not its combination with lisinopril: intake above the 100 mg/day upper limit, sustained over months, is the documented risk, independent of any blood pressure medication.

Why this question comes up

People taking lisinopril for hypertension or heart failure often have overlapping reasons to consider vitamin B6: managing elevated homocysteine, addressing neuropathy from diabetes or isoniazid therapy, or simply taking a multivitamin. General warnings about "supplements and blood pressure medications" get applied broadly, even though they were written with different substances in mind, such as potassium, licorice root, or stimulant-containing weight-loss products, not water-soluble B-vitamins.

How lisinopril works and why that limits interaction risk

Lisinopril blocks the enzyme that converts angiotensin I to angiotensin II, lowering vascular resistance and aldosterone secretion. Unlike some other ACE inhibitors, it is not a prodrug requiring liver activation; it is absorbed intact and eliminated by the kidneys with minimal hepatic metabolism. Because it is not processed through cytochrome P450 enzymes, it has limited opportunity to interact with substances that induce or inhibit those enzymes. Vitamin B6 is not a CYP450 inducer or inhibitor, which is the main pharmacologic reason no meaningful pharmacokinetic interaction is expected between the two.

How vitamin B6 is handled by the body

The liver converts dietary and supplemental B6 into pyridoxal 5'-phosphate (PLP), the active coenzyme form used in amino acid metabolism, neurotransmitter synthesis, and homocysteine handling. B6 is absorbed in the small intestine and excreted renally once tissue stores are saturated. It does not require hepatic CYP450 metabolism, which is consistent with the absence of a documented drug interaction with lisinopril specifically.

The homocysteine angle

PLP is a cofactor in the pathway that converts homocysteine to cysteine. Elevated homocysteine is an independent cardiovascular risk marker, and some patients on lisinopril for cardiovascular reasons are also taking B-vitamins to address it. Large B-vitamin combination trials, including a well-known cardiovascular outcomes trial (HOPE-2), have reported measurable homocysteine reduction with B6 as part of a combined folic acid, B6, and B12 regimen, without a clear reduction in cardiovascular events. The exact effect size and trial citation should be verified against the primary NEJM publication before being repeated to a patient as a specific number; this page does not carry a confirmed locator for that figure.

Is there a pharmacodynamic interaction?

A pharmacodynamic interaction would require both agents to act on a shared physiological target. Vitamin B6 does not act on the renin-angiotensin-aldosterone system, and it is not described as a direct vasodilator at typical supplement doses. A small older study reported blood pressure reduction in hypertensive subjects given a substantially higher pyridoxine dose than typical supplementation (well above the 100 mg/day upper limit). That finding, if the original paper is retrieved and confirmed, would still not represent standard supplement use and should not be generalized to a 25-100 mg/day product. At ordinary supplement doses, no additive or antagonistic blood pressure effect has been reliably replicated.

Potassium is the more important ACE inhibitor supplement concern, and B6 is not it

ACE inhibitors reduce aldosterone secretion and can raise serum potassium. Vitamin B6 has no known effect on potassium handling, which separates it from supplements that genuinely deserve caution alongside lisinopril, such as potassium chloride, salt substitutes containing potassium, and potassium-sparing herbal products.

The real safety question: how much B6, from how many sources

The documented risk associated with vitamin B6 is dose-dependent peripheral neuropathy, not an interaction with lisinopril. Case series dating back decades describe sensory neuropathy, numbness, and gait disturbance in people taking large pyridoxine doses (reports commonly cite intake in the hundreds to low thousands of milligrams per day) for extended periods, with partial reversal after stopping. The National Academies of Medicine set the adult UL at 100 mg/day specifically because of this signal. Exact case-level dose thresholds vary between reports and should be confirmed against the primary case series literature before being quoted as a fixed cutoff.

This matters more for someone on lisinopril than the interaction question itself, because the populations who take lisinopril, people with hypertension, diabetes, or chronic kidney disease, already carry elevated baseline risk for peripheral neuropathy from their underlying conditions. Adding a B6 dose above the UL on top of that baseline risk makes new numbness or tingling harder to attribute correctly, and the workup can be delayed if nobody asks about total supplement intake.

Evidence-status interaction assessment

What a clinician or pharmacist should verify before advising a specific patient: total daily B6 intake summed across all products, current eGFR if CKD is present, reason for B6 use (deficiency, neuropathy prophylaxis, homocysteine management), and whether any coexisting neuropathy symptoms predate the supplement.

Dosing and timing

There is no established need to separate lisinopril and vitamin B6 by time of day; no absorption-competition mechanism has been described between them. Typical adult B6 dosing for general supplementation ranges from the RDA (roughly 1.3 to 1.7 mg/day, usually met through diet) up to therapeutic ranges of 25 to 100 mg/day used for specific indications. Isoniazid therapy for tuberculosis is a recognized exception where higher supervised B6 dosing (commonly cited in the 25 to 50 mg/day range) is used specifically to prevent isoniazid-associated neuropathy; guidance on this comes from CDC tuberculosis treatment recommendations rather than from general supplement labeling (CDC MMWR tuberculosis treatment guidance). If a patient is on lisinopril, isoniazid, and pyridoxine together, the isoniazid indication for B6 does not change; the total B6 dose should still be tracked.

Monitoring

Standard lisinopril monitoring, periodic serum creatinine, potassium, and blood pressure, does not need to change solely because a patient adds standard-dose vitamin B6. If a patient's total B6 intake exceeds the 100 mg/day UL for any reason, it is reasonable for a clinician to add a periodic neurological exam (vibration sense, reflexes, gait) and to ask specifically about new numbness or tingling at follow-up visits. Plasma PLP testing exists but is not part of routine monitoring and is generally reserved for suspected toxicity.

Special situations

Chronic kidney disease. Lisinopril dosing is adjusted at reduced eGFR, and reduced renal clearance in advanced CKD is also expected to slow B6 elimination, which plausibly raises accumulation risk at a given dose. Dialysis patients are often maintained on modest, renal-formulated B6 doses under nephrology guidance rather than standalone high-dose supplements; specific product dosing should come from that clinical relationship, not a general article.

Pregnancy. Lisinopril carries an FDA boxed warning against use in pregnancy because of fetal renal toxicity risk, and it is generally discontinued before conception is attempted or as soon as pregnancy is confirmed. Vitamin B6 at low supplemental doses is commonly used for pregnancy-related nausea under obstetric guidance. Because lisinopril should not be continued through pregnancy, the interaction question for this specific pair does not typically arise in that setting.

Older adults. Age raises baseline risk for both ACE-inhibitor-related hyperkalemia and, independently, for neuropathy that could be confused with B6 toxicity. Conservative B6 dosing (well under the 100 mg/day UL) unless a documented deficiency exists is a reasonable general approach, to be confirmed with the prescribing clinician.

What is established, what is plausible, and what is not established

Established: Lisinopril is renally cleared without significant hepatic metabolism. Vitamin B6 has a defined UL of 100 mg/day set because of a documented, dose-dependent peripheral neuropathy signal at higher intakes. No shared metabolic or vascular mechanism connects lisinopril and vitamin B6.

Plausible but not confirmed by a specific study located for this page: That B6's homocysteine-lowering effect provides added cardiovascular benefit specifically in patients already on an ACE inhibitor. That reduced renal clearance in CKD meaningfully changes safe B6 dosing thresholds for that population beyond general renal-vitamin protocols already in clinical use.

Not established: Any interaction, in either direction, between vitamin B6 and lisinopril at standard supplement doses. A specific milligram threshold at which B6 causes neuropathy that applies uniformly to all patients; the case literature shows a range, not a single cutoff.

If you are already taking both

There is no interaction-based reason to stop either lisinopril or vitamin B6. Add up total daily B6 intake across every product you take, including multivitamins, B-complex supplements, and fortified foods, and confirm the total stays at or under 100 mg/day. If it is higher, bring that up with your prescriber or pharmacist rather than adjusting on your own. New tingling, numbness, burning sensations in the hands or feet, or balance problems should prompt a clinical evaluation regardless of which medication or supplement is suspected, since diabetic neuropathy, isoniazid neuropathy, and pyridoxine toxicity can look similar. Report every supplement, including B6, at medication reconciliation visits so your full nutrient intake is visible to your care team.